Table 2. Mechanisms of acquired osimertinib resistance (18-21).
On target |
EGFR mutations: C797S, L718Q, G724S, C79X, L792X, G769X, S768I, G724S, G796S, V834L exon 20 insertion |
EGFR amplification |
Off target |
MET amplification |
HER2 mutation/amplification |
PIK3CA mutation/amplification |
KRAS mutation/amplification |
PTEN mutation |
Cell cycle gene alterations: CCND1, CCND2, CDKN2A, CDK6, CCNE1 |
Small cell transformation |
Squamous translocation |
EGFR, epidermal growth factor receptor.